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Editorial on the Research Topic
Antibiotic Alternatives and Combinational Therapies for Bacterial Infections
“The thoughtless person playing with penicillin treatment is morally responsible for the death
of the man who succumbs to infection with the penicillin-resistant organism.” As Alexander
Fleming predicted in 1945, bacteria have become increasingly resistant to antibiotics. Penicillin
resistance was presumably first reported already in 1940 when Abraham and Chain reported that
an enzyme from bacteria was able to destroy penicillin (Abraham and Chain, 1940). Every now
and then mankind is shelled with news of infections and deaths caused by antibiotic and multiple
drug resistant superbugs. This increase of resistance toward commonly in-use antibiotics, due to
decades of their use, misuse and abuse, is today a global health concern. Research investments on
development of new agents that can fight antimicrobial resistant microorganisms and the advent of
antibiotic failure due to bacterial resistance has raised interest in other non-conventional alternative
therapies.
This Research Topic gathers some of the latest science around antibiotic alternatives and the
effect of combined therapies. The call was launched in July 2017, and open-call papers were
submitted until May 2018. This is the editorial article introducing the 20 accepted publications
addressing the antimicrobial action of varied agents representing the breadth and scope of research
in this topic.
A high number of publications address the antibacterial use of bacteriophages. A mini
review by Morozova et al. describes the main outcomes of English and Russian case reports
regarding bacteriophage use in infected wounds, burns and trophic ulcers. The antimicrobial
assessment of bacteriophage therapy include in vitro testing toward biofilms of Klebsiella
pneumoniae isolated from diabetic foot patients (Taha et al.), Staphylococcus aureus biofilms
(Kumaran et al.), and their combined use with honey to control dual species biofilms of
Pseudomonas aeruginosa and Escherichia coli in an ex vivo wound model (Oliveira et al.).
Overall, bacteriophages were able to decrease bacterial loads and destroy biofilm structures.
Bacteriophage-antibiotic treatment order was investigated by Kumaran et al. and this greatly
influenced the treatment outcome, and bacteriophages always augmented the activity of antibiotics.
Ujmajuridze et al. screened cultures of patients planned for transurethral resection of prostate,
adapted the commercial Pyo bacteriophage preparation to target the main species identified
(S. aureus, E. coli, Streptococcus spp., P. aeruginosa, and Proteus mirabilis), administered the
preparation via intravesical delivery in nine patients, and observed bacterial decrease in six
of the nine patients treated. In vivo use of a purified bacteriophage capsule depolymerase to
treat E. coli infections in a mouse thigh model was also studied (Lin et al.). In this work, the
authors show that E. coli infections, usually lethal to mice, were effectively treated with an
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enzyme dose of 20 µg per mouse; however this effect was enzyme
and capsule type dependent.
Three original research articles assessed the use of probiotics
such as Lactobacillus plantarum or L. rhamnosus. Wang et
al. describe the diverse roles of L. plantarum from enhancing
the intestinal barrier function, inducing the secretion of
antimicrobial peptides that protect against pathogens, improving
the gut bacterial ecology and barrier function in weaned piglets.
The efficacy of L. plantarum in preventing enterotoxigenic E.
coli growth and inhibiting its adhesion to a porcine intestinal
epithelial cell line was also assessed (Wang et al.). L. rhamnosus
was reported to reduce the adhesion of E. coli to bovine
mammary epithelial cells devoid of the caspase recruitment
domain by supressing the NLRP3 and NLRP4 inflammasomes
and inhibiting E. coli-induced cell pyroptosis (Wu et al.).
Defraine and colleagues reported extensive P. aeruginosa
membrane damage caused by a novel anti-persister molecule
(Defraine et al.) and its antibacterial effect together with
different classes of antibiotics toward clinically relevant ESKAPE
pathogens (Defraine et al.). The molecule used (SPI009) has
great potential to inhibit biofilm growth and eradicate both
P. aeruginosa and S. aureus biofilms, and improved nematode
survival when tested in Caenorhabditis elegans infected with P.
aeruginosa. Vitamin C was shown to have antibiofilm activity
against Bacillus subtilis by reducing the extracellular polymeric
substance biosynthesis, with cells becoming more susceptible for
killing (Pandit et al.).
An original article by Klitgaard et al. identified potential genes
that could be suitable as targets for ciprofloxacin potentiating
compounds, and found that in targeting the AcrAB-TolC eﬄux
pump and the SOS response proteins RecA and RecC, E.
coli resistance to ciprofloxacin was reverted in intermediate
susceptible strains.
Antibiotic derivatives were reported by Ramchuran et al.,
who used three teixobactin derivatives to inhibit methicillin-
resistant S. aureus (MRSA) growth, giving evidence of its
dominant binding mode to lipid II. Antibiotic combinations
against established S. aureus biofilms were also studied in a
hollow fiber infection model. However, no beneficial effect of
combination therapy compared to the most effective antibiotic
was observed, though the addition of the second antibiotic
reduced the rise of bacterial resistant to the first drug (Broussou
et al.). Anti-MRSA activity using cationic nanostructured lipid
carriers combined with antibiotic was evaluated in mice models
of cutaneous infection resulting in infection reduction and
improvement of skin barrier function and architecture (Alalaiwe
et al.). The topical efficacy and safety of chitogel assembled
together with an iron chelator and with a novel broad spectrum
antimicrobial effectively reduced S. aureus biofilms in an in vivo
sheep model without causing any topical or systemic adverse
effects (Ooi et al.). The topical treatment of recalcitrant chronic
rhinosinusitis using colloidal silver was assessed through a 10-
day program where patients performed rinsing twice daily (Ooi
et al.). Despite being safe, the group of treated patients had
similar improvement in symptoms and endoscopic scores as
those in the control groups and were inferior to culture-directed
oral antibiotics. Tran et al. used an antineoplastic mitotane, that
permeabilize the outer membrane of P. aeruginosa, Acinetobacter
baumannii and K. pneumoniae, to exert greater effect to a novel
polymyxin, and reduce the emergence of antibiotic-resistant
phenotypes.
Three branched RRWQWR-based cationic peptides
were designed, synthesized and evaluated revealing higher
antibacterial activity against clinically relevant pathogens than
the reference peptide (Vega et al.).
We hope that you enjoy reading this Research Topic and find
it a useful reference for the state of the art in the emerging field of
antibiotic alternatives.
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